Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):83–88. doi: 10.1054/bjoc.2000.1311

Modulation of paclitaxel resistance by annexin IV in human cancer cell lines

E Kyu-Ho Han 1,#, S K Tahir 1,#, S P Cherian 1, N Collins 1, S-C Ng 1
PMCID: PMC2374538  PMID: 10883672

Abstract

A recurring problem with cancer therapies is the development of drug resistance. While investigating the protein profile of cells resistant to a novel antimitotic compound (A204197), we discovered an increase in annexin IV expression. When we examined the annexin IV protein expression level in a paclitaxel-resistant cell line (H460/T800), we found that annexin IV was also overexpressed. Interestingly a closely related protein, annexin II, was not overexpressed in H460/T800 cells. Immunostaining with either annexin II or IV antibody revealed that annexin IV was primarily located in the nucleus of paclitaxel-resistant H460/T800 cells. Short-term treatment of H460 cells with 10 nMpaclitaxel for up to 4 days resulted in induction of annexin IV, but not annexin II expression. In addition, there was an increase in annexin IV staining in the nucleus starting at day 1. Furthermore, cells pretreated with 10 nMpaclitaxel for 4 days resulted in cells becoming ~fivefold more resistant to paclitaxel. Transfection of annexin IV cDNA into 293T cells revealed that there was a threefold increase in paclitaxel resistance. Thus our results indicate that annexin IV plays a role in paclitaxel resistance in this cell line and it is among one of the earliest proteins that is induced in cells in response to cytotoxic stress such as antimitotic drug treatment. © 2000 Cancer Research Campaign

Keywords: annexin, paclitaxel, drug resistance, antimitotic

Full Text

The Full Text of this article is available as a PDF (884.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barwise J. L., Walker J. H. Annexins II, IV, V and VI relocate in response to rises in intracellular calcium in human foreskin fibroblasts. J Cell Sci. 1996 Jan;109(Pt 1):247–255. doi: 10.1242/jcs.109.1.247. [DOI] [PubMed] [Google Scholar]
  2. Benz J., Hofmann A. Annexins: from structure to function. Biol Chem. 1997 Mar-Apr;378(3-4):177–183. [PubMed] [Google Scholar]
  3. Blagosklonny M. V., Schulte T. W., Nguyen P., Mimnaugh E. G., Trepel J., Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995 Oct 15;55(20):4623–4626. [PubMed] [Google Scholar]
  4. Cabral F., Abraham I., Gottesman M. M. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4388–4391. doi: 10.1073/pnas.78.7.4388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cole S. P., Pinkoski M. J., Bhardwaj G., Deeley R. G. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer. 1992 Apr;65(4):498–502. doi: 10.1038/bjc.1992.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dubois T., Oudinet J. P., Mira J. P., Russo-Marie F. Annexins and protein kinases C. Biochim Biophys Acta. 1996 Oct 11;1313(3):290–294. doi: 10.1016/0167-4889(96)00102-4. [DOI] [PubMed] [Google Scholar]
  7. Germann U. A. P-glycoprotein--a mediator of multidrug resistance in tumour cells. Eur J Cancer. 1996 Jun;32A(6):927–944. doi: 10.1016/0959-8049(96)00057-3. [DOI] [PubMed] [Google Scholar]
  8. Giannakakou P., Sackett D. L., Kang Y. K., Zhan Z., Buters J. T., Fojo T., Poruchynsky M. S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997 Jul 4;272(27):17118–17125. doi: 10.1074/jbc.272.27.17118. [DOI] [PubMed] [Google Scholar]
  9. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  10. Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988 Sep 5;263(25):12163–12166. [PubMed] [Google Scholar]
  11. Haber M., Burkhart C. A., Regl D. L., Madafiglio J., Norris M. D., Horwitz S. B. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem. 1995 Dec 29;270(52):31269–31275. doi: 10.1074/jbc.270.52.31269. [DOI] [PubMed] [Google Scholar]
  12. Han E. K., Begemann M., Sgambato A., Soh J. W., Doki Y., Xing W. Q., Liu W., Weinstein I. B. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ. 1996 Jun;7(6):699–710. [PubMed] [Google Scholar]
  13. Han E. K., Sgambato A., Jiang W., Zhang Y. J., Santella R. M., Doki Y., Cacace A. M., Schieren I., Weinstein I. B. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene. 1995 Mar 2;10(5):953–961. [PubMed] [Google Scholar]
  14. Kavallaris M., Burkhart C. A., Horwitz S. B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer. 1999 Jun;80(7):1020–1025. doi: 10.1038/sj.bjc.6690507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kavallaris M., Kuo D. Y., Burkhart C. A., Regl D. L., Norris M. D., Haber M., Horwitz S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997 Sep 1;100(5):1282–1293. doi: 10.1172/JCI119642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lee J. S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A. T., Bates S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol. 1994 Oct;46(4):627–638. [PubMed] [Google Scholar]
  17. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996 Jun;32A(6):912–920. doi: 10.1016/0959-8049(96)00069-x. [DOI] [PubMed] [Google Scholar]
  18. Mohiti J., Caswell A. M., Walker J. H. Calcium-induced relocation of annexins IV and V in the human osteosarcoma cell line MG-63. Mol Membr Biol. 1995 Oct-Dec;12(4):321–329. doi: 10.3109/09687689509072434. [DOI] [PubMed] [Google Scholar]
  19. Nygren P., Larsson R., Gruber A., Peterson C., Bergh J. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer. 1991 Dec;64(6):1011–1018. doi: 10.1038/bjc.1991.456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. O'Farrell P. H. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975 May 25;250(10):4007–4021. [PMC free article] [PubMed] [Google Scholar]
  21. Ranganathan S., Benetatos C. A., Colarusso P. J., Dexter D. W., Hudes G. R. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998 Feb;77(4):562–566. doi: 10.1038/bjc.1998.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ranganathan S., Dexter D. W., Benetatos C. A., Chapman A. E., Tew K. D., Hudes G. R. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 1;56(11):2584–2589. [PubMed] [Google Scholar]
  23. Ranganathan S., Dexter D. W., Benetatos C. A., Hudes G. R. Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. Biochim Biophys Acta. 1998 Jan 21;1395(2):237–245. doi: 10.1016/s0167-4781(97)00168-1. [DOI] [PubMed] [Google Scholar]
  24. Raynal P., Kuijpers G., Rojas E., Pollard H. B. A rise in nuclear calcium translocates annexins IV and V to the nuclear envelope. FEBS Lett. 1996 Sep 2;392(3):263–268. doi: 10.1016/0014-5793(96)00827-7. [DOI] [PubMed] [Google Scholar]
  25. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  26. Rowinsky E. K., Onetto N., Canetta R. M., Arbuck S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992 Dec;19(6):646–662. [PubMed] [Google Scholar]
  27. Schibler M. J., Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J Cell Biol. 1986 Apr;102(4):1522–1531. doi: 10.1083/jcb.102.4.1522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sjölin C., Stendahl O., Dahlgren C. Calcium-induced translocation of annexins to subcellular organelles of human neutrophils. Biochem J. 1994 Jun 1;300(Pt 2):325–330. doi: 10.1042/bj3000325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  30. Smith P. D., Moss S. E. Structural evolution of the annexin supergene family. Trends Genet. 1994 Jul;10(7):241–246. doi: 10.1016/0168-9525(94)90171-6. [DOI] [PubMed] [Google Scholar]
  31. Wang T. H., Wang H. S., Ichijo H., Giannakakou P., Foster J. S., Fojo T., Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 1998 Feb 27;273(9):4928–4936. doi: 10.1074/jbc.273.9.4928. [DOI] [PubMed] [Google Scholar]
  32. Wolfson M., Yang C. P., Horwitz S. B. Taxol induces tyrosine phosphorylation of Shc and its association with Grb2 in murine RAW 264.7 cells. Int J Cancer. 1997 Jan 17;70(2):248–252. doi: 10.1002/(sici)1097-0215(19970117)70:2<248::aid-ijc17>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  33. Yang C. P., Galbiati F., Volonte D., Horwitz S. B., Lisanti M. P. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett. 1998 Nov 20;439(3):368–372. doi: 10.1016/s0014-5793(98)01354-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES